MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced the issuance of U.S. Patent No. 7,425,448, with broad claims to cardiomyocytes derived from human embryonic stem cells (hESCs). The patent runs until at least April 2025 (subject to any patent term extension that may be available). Geron’s GRNCM1 program is developing hESC-derived cardiomyocytes for the treatment of heart disease.
